Related Experiment Videos

Statins and congestive heart failure

Jennifer Martin1

  • 1Royal Brisbane Women's Hospital Department of Medicine/Diamantina Institute, University of Queensland, 4006, Australia. Jennifer_H_Martin@health.qld.gov.au

Current Atherosclerosis Reports
|August 19, 2008
PubMed

Insights

The Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) found no survival benefit for statin therapy in patients with ischemic systolic heart failure (HF). This challenges previous retrospective findings on statins for HF prevention and treatment.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Trials

Background:

  • Post hoc analyses suggest statins benefit heart failure (HF) patients.
  • Prospective data on statins for HF morbidity and survival were limited before 2007.

Purpose of the Study:

  • To evaluate the impact of statin therapy on heart failure (HF) morbidity and survival.
  • To critically assess recent literature on statins in HF, considering potential biases.

Main Methods:

  • The Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) was a large-scale prospective trial.
  • The study focused on patients with ischemic systolic HF treated with low-dose rosuvastatin.

Main Results:

  • The CORONA trial reported no survival benefit in patients with ischemic systolic HF receiving low-dose rosuvastatin.
  • Existing retrospective data on statins for HF present uncertainties due to potential biases and lack of mechanistic data.

Conclusions:

  • The CORONA trial results introduce uncertainty regarding statin efficacy in specific HF populations.
  • Further investigation is needed to clarify the role of statins in heart failure management, addressing data limitations.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...